Introduction
A cardioprotective effect for v3 fatty acids derived from fish oil is supported by prospective studies demonstrating inverse associations between fish intake and coronary heart disease mortality [1] [2] [3] [4] , especially amongst highrisk individuals [5] . Early separation of survival curves in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico (GISSI) trial [6] and Diet and Reinfarction Trial (DART) [7] support a reduction in ventricular fibrillation and a decreased incidence of myocardial infarction [8] as the primary mechanisms through which v3 fatty acids prevent cardiovascular disease. Clinical trials and experimental studies, however, suggest important antiatherogenic and antithrombotic effects. These result from wide-ranging biological effects, including benefits on lipoprotein metabolism [9] , blood pressure [10, 11] , endothelial function and vascular reactivity [10, 12] , inflammation [13 ] , platelet [14] and fibrinolytic function [15] , cytokine production [16] , coagulation [17] and oxidative stress [18 ] .
The favourable effects of fish oils were primarily attributed to eicosapentaenoic acid (EPA) [19] , despite the fact that some fish provide substantial quantities of docosahexaenoic acid (DHA). Even until recently, it was unclear as to whether EPA or DHA, the two principal v3 fatty acids, were equally important in relation to cardiovascular protection. A limiting factor has been the lack of sufficient quantities of purified EPA or DHA, resulting in the individual effects of EPA and DHA in humans being examined in only a few controlled trials. These data now demonstrate that DHA, like EPA, has important haemodynamic and anti-atherogenic properties.
This review summarizes the individual effects of EPA and DHA on cardiovascular risk factors in trials in humans in which oils with 90% or higher purity have been used. The review addresses potential mechanisms for the effects of EPA and DHA, drawing data from the literature and from our own controlled studies that assessed the independent effects of EPA and DHA in overweight hyperlipidaemic men and in treated-hypertensive type 2 diabetic men and women. There are a number of EPA and DHA-enriched oils presently available for research trials, although some of these oils are also contaminated with other saturated and polyunsaturated fatty acids. Consequently these oils are not suitable for evaluating the independent effects of EPA and DHA. Trials using these oils are listed but will not be discussed in detail.
Method of review
Clinical intervention studies supplementing purified EPA or DHA were identified using Medline searches from 1966 until present and by cross-referencing of these publications. Keywords used were eicosapentaenoic acid, docosahexaenoic acid, purified fish oil, EPA and DHA, and only papers written in English were considered. This review focuses on controlled studies, defined as those in which either a placebo or comparison group of subjects was employed (Table 1 ) [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] . Parallel and crossover designs were considered. Since there are limited controlled data available for the individual effects of EPA and DHA on certain risk factors, uncontrolled studies are also listed (Table 2 ) .
Plasma and platelet phospholipids
Supplementation with purified EPA significantly increased EPA in plasma phospholipids by approximately 96 Lipid metabolism 390% [23, [26] [27] [28] [29] . These studies used 3-4 g/day of EPA and were 6-7 weeks in duration. Docosapentaenoic acid (DPA) content was approximately doubled, while DHA decreased by approximately 16%. Similar changes were observed in two controlled trials that reported changes in platelet phospholipids [22, 26] . In these studies, EPA supplementation caused a 370% increase in EPA, a 50% increase in DPA and a 30% decrease in DHA. These changes were associated with small but significant decreases (approximately 15%) in v3 fatty acids, particularly arachidonic acid.
Controlled studies of DHA supplementation increased DHA by approximately 150% in both plasma and platelet phospholipids, and decreased DPA by approximately 50% [22, 23, 26, 28, 29, [34] [35] [36] . At the same time, EPA increased by approximately 50% and 100% in plasma and platelet phospholipids respectively [22, 23, 26, 28, 29, 32, [34] [35] [36] demonstrating retro-conversion of DHA to EPA. This effect did not appear to be related to study duration but a threshold dose may exist since no changes in EPA occurred in plasma phospholipids when using 0.75 and 1.5 g/day of DHA [32] . Linoleic acid remained Omega-3 fatty acids and cardioprotection Mori and Woodman 97 unchanged in both plasma and platelet phospholipids whilst arachidonic acid decreased by approximately 20% in plasma and 10% in platelets [22, 26, 34, 36] .
Plasma lipids and lipoproteins
Five controlled studies examined the effects of purified EPA on serum lipids and lipoproteins [23, 24, 26, 29, 31] . Supplementation with 4 g daily EPA reduced triglycerides by 21% [24] and 23% [26] in mildly hyperlipidaemic subjects, by 19% in type 2 diabetic individuals [23] and by 12% in healthy subjects [29] . A lower dose of 1.8 g/day EPA for 16 weeks was ineffective in patients with angina and elevated triglyceride levels [31] . Most uncontrolled studies (Table 2 ) also showed a significant decrease in triglycerides, the mean fall being 24% (range 14-35%).
EPA supplementation has had little effect on total cholesterol, LDL cholesterol and HDL cholesterol levels. One study, however, observed a small but significant 2.5% decrease in total cholesterol [29] . Although HDL cholesterol has not been altered by EPA supplementation, HDL 3 cholesterol decreased in dyslipidaemic [26] and type 2 diabetic [23] patients, and HDL 2 cholesterol increased in type 2 diabetic patients [23] . In the only two controlled studies examining LDL particle size, EPA had no effect [21, 26] . Uncontrolled studies demonstrated larger decreases (approximately 10%) in total cholesterol and LDL cholesterol, but no change in HDL cholesterol.
DHA supplementation reduced triglycerides in most controlled studies by approximately 17-33% [23, 24, 26, 29, 35, 36] , the largest decrease occurring in subjects with the highest baseline triglycerides (1.6 mmol/L) [26] . Studies in which triglycerides were unchanged used lower purity DHA [32, 37] , a relatively low dose (< 2 g/day) [32] and were carried out in participants with triglyceride levels that were normal at baseline [37] . Uncontrolled studies show a consistent decrease in triglycerides of approximately 20% [38] [39] [40] 68, 70] .
All controlled studies using purified DHA have reported no change in total cholesterol [23, 24, 26, 29, 32, [35] [36] [37] .
No change occurred in dyslipidaemic (cholesterol of 6.0 mmol/L) [26] or type 2 diabetic [23] subjects after 6 weeks of 4.0 g/day DHA, or in studies using 0.75-6.0 g/ day DHA for 3-14 weeks duration in normocholesterolaemic subjects [29] . LDL cholesterol was unchanged in all but one study in dyslipidaemic subjects [26] , which showed an 8% increase. HDL cholesterol increased in two studies by 4% [29] and 17% [36] . DHA increased HDL 2 cholesterol by 37% in dyslipidaemic patients [26] and by 12% in type 2 diabetic patients [23] . A DHAenriched supplement (42% DHA) also increased HDL 2 cholesterol by 19% [35] . HDL 3 cholesterol did not change in any study.
Studies supplementing dyslipidaemic [26] or type 2 diabetic [21] subjects with 4.0 g/day DHA for 6 weeks, increased LDL particle size, in contrast to EPA.
The data demonstrate that both EPA and DHA reduce blood triglycerides. Whilst HDL cholesterol remained unaltered in most studies, EPA and DHA have differential effects on the HDL sub-fractions. Overall EPA and DHA supplementation promotes an antiatherogenic shift in HDL particle size. An increase in HDL 2 cholesterol is most likely following DHA and a reduction in HDL 3 cholesterol more likely after EPA. A significant increase in LDL particle size following DHA supplementation demonstrates that the lipid-regulating effects of DHA are at least as important as those of EPA. LDL particle size is an important cardiovascular risk factor [72] and correlates with sub-clinical atherosclerosis as measured by intimamedia thickening [73] . Whilst the average increase in LDL particle size with DHA of 0.26 nm [21, 26] appears relatively small, a significant difference in size of only 1.02 nm was found between middle-aged healthy men with no risk factors and men with the metabolic syndrome [73] . The predominant determinants of LDL particle size are triglycerides and HDL cholesterol, and changes in these variables are also the predominant predictors of change in LDL size. The differential effects on LDL particle size following EPA and DHA cannot, however, be explained by the reduction in triglycerides alone since both EPA and DHA reduce triglycerides by a similar extent. Additionally, the association between the change in LDL size and triglycerides is only weak [21] . Few fish oil studies have examined cholesterol-ester transfer protein (CETP) and hepatic lipase activity, which are major determinants of both LDL and HDL particle size. Uncontrolled data demonstrated a reduction in CETP and a concomitant increase in the HDL 2 /HDL 3 ratio following EPA supplementation, although no correlation was reported [54] . Since a reduction in CETP activity would lead to an increase in the LDL size as well as the HDL 2 /HDL 3 ratio, the data [21, 26] are suggestive of a greater reduction of CETP activity with DHA than with EPA, although this requires further investigation.
Blood pressure and endothelial function
Randomized controlled trials provide unequivocal evidence that v3 fatty acids reduce blood pressure, particularly in hypertensive patients [10] . A meta-analysis of clinical trials assessing the effects of fish oils showed DHA had a slightly greater dose-response effect than EPA on blood pressure (À1.5/À0.77 mmHg versus À0.93/ À0.53 mmHg per gram) [74] . In spontaneously hypertensive rats, whilst both EPA and DHA retarded the development of hypertension, purified DHA was more effective than either purified EPA or a combination of EPAþDHA [75] .
Five controlled studies assessed the effects of purified EPA on blood pressure in humans [23, 24, 27, 30, 31] . No effects were observed in healthy subjects [30] , those with dyslipidaemia [24] , patients with angina [31] or patients with type 2 diabetes mellitus [23] . In contrast, Mori et al. [27] showed that DHA, but not EPA, significantly lowered 24-h ambulatory systolic and diastolic blood pressure in overweight, mildly-hypercholesterolaemic subjects. Fifty-six subjects were randomized to receive 4 g/day of purified EPA, DHA or olive oil for 6 weeks. Only DHA significantly reduced 24-h (À5.8/À3.3 mmHg) and daytime (awake) (À3.5/À2.0 mmHg) blood pressure, relative to placebo [27] . These effects were accompanied by significant improvements in endothelial and smooth muscle function in the forearm microcirculation with DHA but not EPA, as well as reduced vasoconstrictor responses [12] . Failure to detect changes in blood pressure in other controlled studies using DHA is most likely due to use of a lower dose, concomitant use of pharmacological agents, an inadequate sample size, increased blood pressure variability resulting in inadequate statistical power and the choice of placebo oil.
There is considerable evidence supporting a beneficial effect of v3 fatty acids on vascular function [10] . Both purified EPA [31] and DHA [12] have proved beneficial in this respect. Whilst release of nitric oxide is the main factor affecting flow-mediated dilatation in conduit vessels, v3 fatty acids alter vascular function by additional mechanisms including changes in the release of ADP, endothelium-derived hyperpolarizing factor and prostanoids [10] . Mori et al. [12] showed that the reduction in blood pressure following DHA supplementation in overweight, hypercholesterolaemic subjects [27] was associated with significant improvements in endothelial and smooth muscle function. Dilator and constrictor responses were improved in the forearm microcirculation with DHA but not with EPA [12] . Indirect evidence for a beneficial effect of DHA but not EPA on endothelial function was also obtained by measuring serum and urinary nitrate output [46] . Healthy volunteers received 64% pure fish oil concentrate or 91% pure EPA ethyl esters for 3 weeks. There was no change in creatinine-adjusted serum nitrate levels or nitrate excretion in the EPA group, whereas nitrate excretion increased significantly in the fish oil concentrate group. These results are only suggestive of increased nitric-oxide production in endothelial cells, however, since nitrates are also derived from other sources.
Whilst no controlled studies have demonstrated reductions in blood pressure using purified EPA, improvements in endothelial function of the coronary arteries were observed in a controlled study of patients with variant angina [31] . EPA improved vasomotion at coronary sites exhibiting a slight vasoconstriction, but was unable to prevent the persistence of vasospasms at severely constricting sites [31] . Blood pressure is strongly influenced by arterial compliance, which in turn is influenced by endothelial function. In this regard, EPA and DHA both improved arterial compliance by 35% and 27% respectively in patients with dyslipidaemia after 7 weeks of supplementation [24] . Whilst only the EPA effect was statistically significant, there was no significant difference in the effect between EPA and DHA.
Heart rate
A low dose of v3 fatty acids decreased sudden cardiac death by 45% in the GISSI-Prevenzione trial [6] . This effect may have been as a result of stabilizing myocardial membranes and reducing susceptibility to ventricular arrhythmias [8] . The latter effect may be related to the reduction in heart rate usually found with v3 fatty acids [10, 76 ] and suggests a significant cardiac component associated with the antihypertensive effects, possibly mediated by effects on autonomic nerve function or b-adrenoreceptor activity. Mori et al. [27] demonstrated that heart rate was reduced using DHA, but not EPA. The authors showed that in overweight, mildly hyperlipidaemic, but otherwise healthy men given 4 g daily EPA, DHA or olive oil for 6 weeks, 24-h, awake and asleep heart rate fell 3.5, 3.7 and 2.8 bpm, respectively, following DHA [27] . Interestingly, EPA resulted in a small, albeit non-significant rise in heart rate. These differential effects of EPA and DHA on heart rate were substantiated by Grimsgaard et al. [30] . Similarly, Woodman et al. [23] showed that DHA, but not EPA, significantly reduced clinic standing and supine heart rates (À5.8 and À3.9 bpm, respectively) compared with placebo.
Platelet aggregation
The study of Woodman et al. [22] in type 2 diabetic patients was the first controlled study to examine the effects of purified EPA supplementation on platelet aggregation in humans. Neither collagen nor platelet activating factor-induced responses were altered in ex-vivo platelet aggregation studies [22] .
In contrast, uncontrolled studies using EPA have consistently reduced ex-vivo platelet aggregation to collagen by 20-30% using a minimum of 1.8 g/day over periods of as little as 6 days [41, 42, 50, 56, 61, 62, 64, 65] . All but one of these studies, that of Miwa et al. [50] , were performed in non-diabetic individuals, which might account for the lack of effect of EPA in the study by Woodman et al. [22] . Individuals with type 2 diabetes have an increased predisposition to platelet aggregation and are resistant to changes in aggregation [77] . The potential to reduce platelet aggregation in type 2 diabetic individuals may also be limited by the unilateral use of anti-hypertensive treatments, many of which are known to improve platelet function. Uncontrolled studies have also shown significant reductions (22-64%) in blood but not urinary thromboxane B 2 . Reductions in platelet aggregation to ADP, epinephrine and arachidonic acid have been inconsistent.
The study conducted by Woodman et al. [22] was also the first controlled study to examine the effects of purified DHA supplementation on platelet aggregation in humans. It showed that in type 2 diabetic patients, a reduction in collagen-induced aggregation is mediated largely by decreased platelet thromboxane B 2 release. Two other controlled studies using lower purity DHA supplements (1.68 g/day and 1.62 g/day DHA) in healthy individuals failed to reduce collagen and ADP-induced aggregation [36] or collagen-stimulated thromboxane B 2 release [33, 36] . Both studies, however, involved healthy subjects who might be expected to have normal platelet function. In contrast, in a short-term uncontrolled study in healthy individuals, higher doses of DHA (6 g/day) have reduced platelet aggregation to collagen and ADP [42] . DHA given as 6 g daily to healthy men for 90 days also reduced urinary thromboxane B 2 excretion [66] .
The reduction in platelet and urinary thromboxane B 2 following DHA supplementation may be due to competitive inhibition of cyclooxygenase [78] , inhibition of thromboxane A 2 synthetase or inhibition of thromboxane A 2 receptor function [79, 80] . This could explain the greater effect of DHA compared with EPA on platelet aggregation [22] . In contrast, EPA is converted to thromboxane A 3 , a less potent aggregator of platelets than is thromboxane A 2 . The lack of effect of DHA in studies using 1-2 g daily also suggests a threshold dose may be required to inhibit enzymatic activity.
Aggregatory responses to other agonists following DHA supplementation have varied. In this regard, Woodman et al. observed no effect of DHA on platelet activating factor-induced aggregation [22] , which may be due, in part, to the fact that this pathway is less dependent on cyclooxygenase.
Platelet and endothelial activation
Endothelium-derived von Willebrand factor and plateletderived P-selectin are integral in the initial stages of platelet adhesion to the endothelium. Woodman et al. [22] demonstrated that both highly purified EPA and DHA induced small non-significant reductions in P-selectin in type 2 diabetic individuals. Neither EPA nor DHA, however, altered von Willebrand factor [22] . In contrast, Park et al. [25] showed that mean platelet volume, a marker of platelet activation, was decreased by EPA, but not DHA, supplementation. Platelet count was also increased by EPA and not DHA [25] .
Fibrinolysis
Neither highly purified EPA nor DHA had any significant effect on plasma plasminogen activator inhibitor (PAI)-1 antigen, tissue-type plasminogen activator (tPA) antigen or the tPA/PAI-1 ratio [22] . No change was observed in plasma fibrinogen in two controlled DHA studies with healthy subjects using relatively low doses [33, 36] . Similarly, there was no change in PAI-1 activity with either DHA or EPA supplementation in a large doubleblind trial with healthy middle-aged men [38] . In an uncontrolled study in patients with a stenosis, EPA supplementation reduced PAI-1 antigen (26%) and tPA antigen (18%) [49] .
Glycaemic control, insulin sensitivity and secretion
Disparate findings concerning effects of v3 fatty acids on glycaemic control in type 2 diabetic patients may be related to the dose of v3 fatty acids, oral diabetic medication, the presence of obesity or insulin resistance, the presence of other conditions such as hypertension, not controlling subjects' diets during intervention and the duration of intervention [81, 82] . In support of the latter, self-monitored blood glucose rose following EPA and DHA in the first 3 weeks, but had returned to baseline values by week six [23] .
Two placebo-controlled studies have examined the independent effects of purified EPA and DHA on glucose and insulin in individuals with type 2 diabetes mellitus [23] and in mildly dyslipidaemic men [26] . Mori et al. [26] reported a borderline significant increase in fasting glucose after 6 weeks of 4 g/day EPA (P ¼ 0.06 versus placebo) but no change with 4 g daily DHA. Fasting serum insulin significantly increased relative to placebo in the DHA group but not in the EPA group [26] . Woodman et al. [23] showed that in individuals with type 2 diabetes, fasting glucose was significantly increased by 1.40 mmol/L (19%) and 0.98 mmol/L (12%) relative to placebo, following 6 weeks of 4 g daily EPA or DHA supplementation, respectively. Fasting insulin and Cpeptide were unaltered by either EPA or DHA [23] . Self-monitored blood glucose concentrations, measured four times daily on 4 days of each week throughout the 6-week intervention, were non-significantly increased after EPA, but not DHA, compared with placebo. Neither EPA nor DHA altered HbA 1c [23] . Insulin secretion and insulin sensitivity were unaffected by EPA or DHA during a low-dose insulin glucose infusion regime, suggesting an increase in hepatic glucose output as the most plausible explanation for the impairment in glycaemic control [23] .
Increased hepatic glucose output could be related to the triglyceride-lowering effect of EPA and DHA. Increased peroxisome proliferator-activated receptor (PPAR)a with EPA leads to increased hepatic uptake and oxidation of free fatty acids in vitro [83] , as well as increased skeletal muscle fatty acid oxidation [84] . The consequent decrease in free fatty acid availability should decrease triglyceride synthesis, while an increase in hepatic free fatty acid oxidation could both increase hepatic gluconeogenesis [85] and also decrease glucose oxidation via the Randle glucose-fatty acid cycle [86] . In addition, increased hepatic mitochondrial b-oxidation occurred with EPA but not DHA after both fatty acids elevated PPARa in rat hepatocytes [83] . This may explain the greater tendency of EPA to increase fasting glucose in mildly dyslipidaemic men [26] and self-monitored blood glucose in type 2 diabetic individuals [23] .
Inflammation
Experimental and clinical studies provide evidence that v3 fatty acids are anti-inflammatory and immunomodulatory, making these fatty acids potential therapeutic agents for inflammatory and autoimmune diseases [13 ] . In this regard, ex-vivo production of TNFa, IL-1 and IL-6 following lipopolysaccharide stimulation of monocytes/lymphocytes is reduced following v3 fatty acids [13 ] . In-vitro studies have also shown that DHA but not EPA decreased the expression of pro-inflammatory cytokines, cell-adhesion molecules and monocyte adhesion to endothelial cells [87] . Omega-3 fatty acids attenuated the expression of adhesion molecules on the surface of cultured human endothelial cells, monocytes and lymphocytes [87] . In particular, DHA was more potent than EPA in inhibiting expression of vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1) and E-selectin, after stimulation with stimuli able to elicit the expression of these genes. The effects of DHA on VCAM-1 expression were accompanied by parallel reductions in VCAM-1 mRNA [87] . The EPA and DHA-induced reduction in adhesion molecule expression was accompanied by decreased binding of human lymphocytes and monocytes to cytokine-stimulated endothelial cells [87] .
To date, one study has examined the independent effects of purified EPA and DHA on markers of inflammation in humans. Mori et al. [20] showed that although neither purified EPA nor DHA given 4 g daily for 6 weeks to type 2 diabetic individuals significantly reduced IL-6 or C-reactive protein, both fatty acids reduced TNFa by approximately 25% compared with placebo.
Oxidative stress
There remains a theoretical concern that v3 fatty acids may increase lipid peroxidation and oxidative stress. Mori et al. [18 ] examined the effect of purified EPA or DHA on the excretion of urinary F 2 -isoprostanes, a class of lipid peroxidation products derived from the non-enzymatic free radical oxidation of arachidonic acid in membrane lipids. F 2 -isoprostanes are considered excellent biomarkers of in-vivo lipid peroxidative damage. Purified EPA or DHA, supplemented as 4 g daily for 6 weeks, decreased urinary F 2 -isoprostane levels by 27% and 26%, respectively, in overweight, mildly hyperlipidaemic men [88] and by 19% and 20%, respectively, in type 2 diabetic individuals [20] . In both studies the changes in F 2 -isoprostanes were unrelated to changes in EPA, DHA, arachidonic acid, total v3 or v6 fatty acids, and thus most likely reflect a true reduction in oxidative stress, rather than a reduction in the supply of substrate.
The mechanisms by which F 2 -isoprostanes are reduced following EPA or DHA remain unresolved, but most likely relate, in part, to decreased leukocyte activation and the immunomodulatory actions of these fatty acids. This hypothesis is supported by data demonstrating that changes in urinary F 2 -isoprostanes were significantly positively associated with changes in TNFa [20] .
Conclusion
The data to date strongly suggest that EPA and DHA have differing haemodynamic and anti-atherogenic properties. Both are equally effective in reducing serum triglycerides, but DHA and not EPA increased HDL cholesterol and, in particular, the HDL 2 cholesterol sub-fraction. Additionally, DHA increased LDL particle size, potentially an antiatherogenic effect. Neither EPA nor DHA affects total cholesterol concentrations. DHA is more effective in reducing blood pressure than EPA and these blood pressure-lowering effects correlate with improvements in endothelial relaxation and attenuated vascular constriction. DHA but not EPA also significantly decreased heart rate, suggesting that this fatty acid may be more important than EPA regarding the anti-arrhythmic effects of v3 fatty acids. Platelet aggregatory responses ex vivo and platelet-derived thromboxane B 2 were reduced by DHA and not EPA, although some reports have shown improvements following EPA. Neither fatty acid alters fibrinolysis, in keeping with findings following fish oil supplementation. Although low doses of EPA or DHA are unlikely to affect blood glucose and insulin concentrations, higher doses, particularly in individuals with type 2 diabetes, may lead to a mild impairment in glycaemic control. The most likely explanation for this effect appears to be an increase in hepatic glucose output since both insulin sensitivity and insulin secretion are unchanged. In-vitro data demonstrating DHA was more potent than EPA in inhibiting expression of cellular/endothelial adhesion molecules have not been reproduced in human trials. Both EPA and DHA attenuated oxidative stress and cytokine production following cell stimulation.
The data in humans suggest that DHA may be more favourable in lowering blood pressure and improving Omega-3 fatty acids and cardioprotection Mori and Woodman 101 vascular function, raising HDL cholesterol and attenuating platelet function. Future studies will need to carefully assess the independent effects of EPA and DHA on other clinical and biochemical measures before decisions can be made with respect to dietary supplements and the fortification of foods with either EPA or DHA. To some extent, however, the effects of EPA and DHA may also differ depending on the target population.
